180 Life Sciences Corp. (ATNF)
- Previous Close
2.3400 - Open
2.3500 - Bid 2.2000 x 100
- Ask 2.3800 x 100
- Day's Range
2.2100 - 2.4500 - 52 Week Range
1.1600 - 17.7500 - Volume
88,911 - Avg. Volume
1,991,614 - Market Cap (intraday)
4.468M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
0.28 - EPS (TTM)
7.9800 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
180lifesciences.comRecent News: ATNF
View MorePerformance Overview: ATNF
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATNF
View MoreValuation Measures
Market Cap
4.63M
Enterprise Value
7.69M
Trailing P/E
0.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.50%
Return on Equity (ttm)
-398.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.55M
Diluted EPS (ttm)
7.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
1.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.45M